Page last updated: 2024-10-16

adenine and Lassitude

adenine has been researched along with Lassitude in 12 studies

Research Excerpts

ExcerptRelevanceReference
"This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)."9.27Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018)
"This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)."5.27Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018)
" In the integrated analysis (ibrutinib treatment up to 43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea (n = 173, 52% any-grade; n = 15, 5% grade 3) and fatigue (n = 119, 36% any-grade; n = 10, 3% grade 3)."2.90Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. ( Barr, PM; Barrientos, JC; Burger, JA; Byrd, JC; Chang, S; Coutre, SE; Dean, JP; Devereux, S; Furman, RR; Ghia, P; Hillmen, P; James, DF; Kipps, TJ; Moreno, C; O'Brien, SM; O'Dwyer, M; Robak, T; Schuh, A; Valentino, R, 2019)
"73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg."2.78Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. ( Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19901 (8.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (75.00)24.3611
2020's2 (16.67)2.80

Authors

AuthorsStudies
Mayer, KH1
Gelman, M1
Holmes, J1
Kraft, J1
Melbourne, K1
Mimiaga, MJ1
Deering, KL1
Sundaram, M1
Harshaw, Q1
Trudeau, J1
Barrientos, JC4
Cramer, P1
Fraser, G1
Santucci-Silva, R1
Grosicki, S2
Dilhuydy, MS1
Janssens, A2
Loscertales, J1
Rule, S1
Goy, A1
Traina, S1
Chan, EKH1
Diels, J1
Sengupta, N1
Mahler, M1
Salman, M1
Howes, A1
Chanan-Khan, A1
Gribben, JG1
Bosch, F1
Cymbalista, F2
Geisler, CH1
Ghia, P3
Hillmen, P4
Moreno, C3
Stilgenbauer, S1
Chari, A1
Larson, S1
Holkova, B1
Cornell, RF1
Gasparetto, C1
Karanes, C1
Matous, JV1
Niesvizky, R1
Valent, J1
Lunning, M1
Usmani, SZ1
Anderson, LD1
Chang, L1
Lee, Y1
Pak, Y1
Salman, Z1
Graef, T1
Bilotti, E2
Chhabra, S1
Coutre, SE2
Byrd, JC3
Barr, PM3
Devereux, S3
Robak, T3
Kipps, TJ3
Schuh, A3
Furman, RR3
Burger, JA3
O'Dwyer, M2
Valentino, R1
Chang, S1
Dean, JP1
James, DF4
O'Brien, SM1
Ruane, PJ1
DeJesus, E1
Berger, D1
Markowitz, M1
Bredeek, UF1
Callebaut, C1
Zhong, L1
Ramanathan, S1
Rhee, MS1
Fordyce, MW1
Yale, K1
Brown, JR1
O'Brien, S2
Kay, NE1
Reddy, NM1
Coutre, S2
Tam, CS2
Mulligan, SP1
Jaeger, U1
Pocock, C1
Thornton, P1
Caligaris-Cappio, F1
Delgado, J1
Schuster, SJ1
Montillo, M1
de Vos, S2
Gill, D1
Bloor, A1
Dearden, C1
Jones, JJ1
Chu, AD1
Fardis, M1
McGreivy, J1
Clow, F2
Blum, KA1
Coleman, M2
Wierda, WG1
Jones, JA1
Zhao, W1
Heerema, NA1
Johnson, AJ1
Shaw, Y1
Zhou, C1
Tedeschi, A1
Owen, C1
Bairey, O1
Bartlett, NL1
Li, J1
Simpson, D1
McCarthy, H1
Quach, H1
Gaidano, G1
Maslyak, Z1
Stevens, DA1
Offner, F1
Mayer, J1
Hellmann, A1
Siddiqi, T1
Polliack, A1
Suri, D1
Cheng, M1
Styles, L1
Noy, A1
Thieblemont, C1
Martin, P1
Flowers, CR1
Morschhauser, F1
Collins, GP1
Ma, S1
Peles, S1
Smith, S1
Smith, A1
Munneke, B1
Dimery, I1
Beaupre, DM1
Chen, R1
KIRZON, MV1
ALLIK, TA1
SHESTAKOV, SV1

Clinical Trials (15)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1[NCT03499483]Phase 452 participants (Actual)Interventional2019-01-24Completed
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia[NCT01109069]Phase 2199 participants (Actual)Interventional2010-06-30Completed
A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247]Phase 1/Phase 2133 participants (Actual)Interventional2010-05-31Completed
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707]Phase 3391 participants (Actual)Interventional2012-06-30Completed
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)[NCT01724346]Phase 3232 participants (Actual)Interventional2012-08-28Completed
Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT01722487]Phase 3269 participants (Actual)Interventional2013-03-31Completed
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370]Phase 410 participants (Actual)Interventional2018-01-08Completed
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]Phase 1/Phase 22 participants (Actual)Interventional2019-04-11Terminated (stopped due to Insufficient accrual)
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410]40 participants (Actual)Observational [Patient Registry]2018-12-01Completed
Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia[NCT03755947]Phase 23 participants (Actual)Interventional2018-12-01Completed
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895]40 participants (Actual)Observational2017-07-21Active, not recruiting
Expression of CD19 Complex in Lymphoproliferative Disorders[NCT04734470]92 participants (Anticipated)Observational2021-03-31Not yet recruiting
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798]Phase 322 participants (Actual)Interventional2019-12-09Active, not recruiting
Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission[NCT05596097]Phase 215 participants (Anticipated)Interventional2022-10-30Not yet recruiting
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma[NCT01980628]Phase 263 participants (Actual)Interventional2013-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Death Event

All death events are due to AE, progressive disease, and other reasons. (NCT01109069)
Timeframe: 30 days after last dose of study drug

InterventionParticipants (Count of Participants)
IBRUTINIB/PCI-3276542

Number of Subjects With Adverse Events

Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

InterventionParticipants (Count of Participants)
A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH199

Progressive Disease (PD)

A progressive disease confirmed by a CT scan. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months

InterventionParticipants (Count of Participants)
IBRUTINIB/PCI-3276570

Food Effect Cohort Assessments

Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.

Intervention (Number)
Food Effect Cohort1.65

Number of Participants With Treatment Emergent Adverse Events (AEs)

Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765

InterventionParticipants (Number)
PCI-32765116
Food Effect11

Percentage of Participants Achieving Response

Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive71
Relapsed/ Refractory75.3
Food Effect56.3

Progression Free Survival Rate at 24 Months

Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).

InterventionPercentage of Participants (Number)
Treatment Naive96.3
Relapsed/ Refractory73.6
Food- EffectNA

OS (Overall Survival)

OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up

Interventionmonths (Median)
Ofatumumab (Arm A)65.1
Ibrutinib (Arm B)67.7

Overall Response Rate (ORR) by Independent Review Committee (IRC)

Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled

Interventionpercentage of participants (Number)
Ofatumumab (Arm A)4.1
Ibrutinib (Arm B)42.6

Overall Response Rate (ORR) by Investigator

Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Interventionpercentage of participants (Number)
Ofatumumab (Arm A)22.4
Ibrutinib (Arm B)87.7

PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013

The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.

Interventionmonths (Median)
Ofatumumab (Arm A)8.1
Ibrutinib (Arm B)NA

Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up

Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

Interventionmonths (Median)
Ofatumumab (Arm A)8.1
Ibrutinib (Arm B)44.1

Rate of Sustained Hemoglobin and Platelet Improvement

Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up

,
Interventionpercentage of participants (Number)
Hgb Improvement in patient with baseline anemiaPlatelet improvement in baseline thrombocytopenia
Ibrutinib (Arm B)69.778.4
Ofatumumab (Arm A)32.69.4

ORR (Overall Response Rate)

ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

Interventionpercentage of participants (Number)
Ibrutinib82.4
Chlorambucil35.3

Overall Survival (OS)

OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionMonths (Median)
IbrutinibNA
ChlorambucilNA

PFS (Progression Free Survival)

"The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS~Progressive disease according to 2008 IWCLL guidelines was defined as:~Group A~Lymphadenopathy, increase ≥50%~Hepatomegaly, increase ≥50%~Splenomegaly, increase ≥50%~Blood lymphocytes, increase ≥ 50% over baseline~Group B~Platelets counts, decrease of ≥ 50% from baseline secondary to CLL~Hemoglobin, decrease of > 2 g/dL from baseline secondary to CLL" (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionMonths (Median)
IbrutinibNA
Chlorambucil18.9

Proportion of Sustained Hemoglobin Improvement

The proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib45.6
Chlorambucil20.3

Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia

In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib84.3
Chlorambucil45.5

Proportion of Sustained Platelet Improvement

The proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib27.2
Chlorambucil11.3

Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia

In randomized subjects with baseline platelet ≤ 100 x 10^9/L, the proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.

InterventionPercentage of Participants (Number)
Ibrutinib77.1
Chlorambucil42.9

Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks

Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks

Interventionng*h/mL (Geometric Mean)
TDF With a Boosted PI3466
TAF With a Boosted PI743
TAF With a Boosted PI and LDV/SOF868

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)

Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks

Interventionfmol/2x7mm punches (Geometric Mean)
TDF With a Boosted PI36014
TAF With a Boosted PI6735
TAF With a Boosted PI and LDV/SOF6100

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks

Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks

Interventionfmol/10^6 cells (Geometric Mean)
TDF With a Boosted PI83.0
TAF With a Boosted PI926
TAF With a Boosted PI and LDV/SOF1129

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR

Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

InterventionmL/min/1.73 m^2 (Geometric Mean)
TDF With a Boosted PI86.7
TAF With a Boosted PI91.0
TAF With a Boosted PI and LDV/SOF88.1

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR

Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Interventionmg/g (Geometric Mean)
TDF With a Boosted PI134
TAF With a Boosted PI118
TAF With a Boosted PI and LDV/SOF97.3

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio

Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

,,
Interventionug/g (Geometric Mean)
β2M:Cr ratioRBP:Cr ratio
TAF With a Boosted PI224242
TAF With a Boosted PI and LDV/SOF178146
TDF With a Boosted PI419436

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

InterventionParticipants (Count of Participants)
Ibrutinib Plus Rituximab0

DOR (Duration of Response)

The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause. (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

InterventionMonths (Median)
IbrutinibNA

ORR (Overall Response Rate)

"ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC).~Per Cheson:~CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites." (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

InterventionPercentage of Participants (Mean)
Single Arm, Intent to Treat Population46

Reviews

1 review available for adenine and Lassitude

ArticleYear
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
    British journal of haematology, 2018, Volume: 180, Issue:5

    Topics: Adenine; Anticoagulants; Antineoplastic Agents; Arthralgia; Atrial Fibrillation; Diabetes Mellitus,

2018

Trials

7 trials available for adenine and Lassitude

ArticleYear
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H
    Leukemia & lymphoma, 2018, Volume: 59, Issue:9

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Bl

2018
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso

2018
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Atrial Fibrillation; Diarrhea; Drug Tolerance; Fati

2019
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
    Journal of acquired immune deficiency syndromes (1999), 2013, Aug-01, Volume: 63, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug;

2013
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal

2014
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2015, Dec-17, Volume: 373, Issue:25

    Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female

2015
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
    Blood, 2017, 04-20, Volume: 129, Issue:16

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Anemia; Antineoplastic

2017

Other Studies

4 other studies available for adenine and Lassitude

ArticleYear
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
    Journal of acquired immune deficiency syndromes (1999), 2022, 05-01, Volume: 90, Issue:1

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3

2022
Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Adenine; Cross-Sectional Studies; Fatigue; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Patient S

2022
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood, 2015, Apr-16, Volume: 125, Issue:16

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Disease-Free Survival; Drug Resistance

2015
[Biochemical characteristics of the skeletal muscles of frogs in different stages of fatigue following single stimulations of the nerve].
    Biulleten' eksperimental'noi biologii i meditsiny, 1962, Volume: 54

    Topics: Adenine; Adenosine Triphosphate; Coenzymes; Fatigue; Lactates; Muscle, Skeletal; Neuromuscular Junct

1962